WGS — GeneDx Holdings Corp. stock price, charts and financials

QT37GeneDx Holdings Corp.

GeneDx Holdings Corp. (NASDAQ: WGS) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
67.86
+2.75+4.22%
OverviewShort InterestFilings
WGSQT37GeneDx Holdings Corp.·NASDAQ
67.86+4.22%
Earnings
Up 4.2% — Reported earnings — EPS missed by 1767%, revenue missed by 9%.
High confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
HTFL+6.06%$26.76PGNY+1.28%$31.53CERT+0.99%$8.18PRVA+0.51%$23.79TDOC-0.37%$6.68OMDA+3.38%$20.51GDRX+2.93%$3.16DOCS+3.59%$21.66
Snapshot
Index-P/E-EPS (ttm)-2.66Insider Own-Shs Outstand29.69MPerf Week10.17%
Market Cap1.93BForward P/E59.26EPS next Y1.10Insider Trans20.52%Shs Float27.41MPerf Month-9.20%
Enterprise Value2.01BPEG-EPS next Q-Inst Own-Short Float21.27%Perf Quarter3.53%
Income-78.67MP/S4.37EPS this Y97.62%Inst Trans-Short Ratio4.44Perf Half Y-33.67%
Sales442.68MP/B7.52EPS next Y1833.73%ROA-15.37%Short Interest5.83MPerf YTD-49.94%
Book/sh-P/C-EPS next 5Y-ROE-27.50%52W High178.11 -61.90%Perf Year-37.10%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-8.07%52W Low33.57 102.14%Perf 3Y787.06%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.12% 19.05%Gross Margin68.35%Volatility8.04% 7.01%Perf 5Y-83.36%
Dividend TTM-EV/Sales4.53EPS Y/Y TTM-37.11%Oper. Margin-7.72%ATR (14)4.59Perf 10Y-
Dividend Ex-Date-Quick Ratio2.95Sales Y/Y TTM45.25%Profit Margin-17.58%RSI (14)53.19Recom2.09
Dividend Gr. 3/5Y-Current Ratio3.09EPS Q/Q-200.00%SMA201.73%Beta1.93Target Price87.43
Payout0.00%Debt/Eq0.66Sales Q/Q17.24%SMA508.55%Rel Volume0.66Prev Close65.11
Employees1,300LT Debt/Eq0.46EarningsAug 03SMA200-28.48%Avg Volume1.34MPrice67.86
IPO DateNov 04, 2020Option/ShortYes / YesEPS/Sales Surpr.-1766.67% -9.07%Net Debt/EBITDA-1.53Volume884,567Change4.22%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-29-26ReiteratedGuggenheimBuy$70 → $74
Jun-23-26ReiteratedPiper SandlerOverweight$130 → $63
May-05-26ReiteratedCraig-HallumBuy$153 → $85
May-05-26ReiteratedCanaccord GenuityBuy$100 → $75
May-05-26ReiteratedWells FargoOverweight$155 → $75
May-05-26ReiteratedGuggenheimBuy$170 → $70
May-05-26ReiteratedBTIGBuy$170 → $90
Apr-20-26ReiteratedCanaccord GenuityBuy$170 → $100
Feb-24-26ReiteratedBTIGBuy$200 → $170
Feb-24-26ReiteratedPiper SandlerOverweight$120 → $130
Latest News
Today
Today02:54AM
DEADLINE TODAY: GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGSprnewswire.com
01:41AM
DEADLINE TODAY: GeneDx Holdings Corp. Investor Alert: Contact SBS by August 3, 2026 for Opportunity to Lead Securities Fraud Lawsuitprnewswire.com
Aug-02-26
Aug-02-2612:00PM
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
09:15AM
WGS DEADLINE TOMORROW: ROSEN, A LONGSTANDING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGSnewsfilecorp.com
Aug-01-26
Aug-01-2611:27AM
WGS DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGSglobenewswire.com
06:15AM
WGS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026newsfilecorp.com
Jul-31-26
Jul-31-2606:17PM
GeneDx Holdings Corp. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against GeneDx Holdings Corp. - WGSbusinesswire.com
02:12PM
WGS DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGSnewsfilecorp.com
02:04PM
GENEDX HOLDINGS DEADLINE MONDAY AUGUST 3rd: Bragar Eagel & Squire, P.C. Urges GeneDx Holdings Corp. Investors to Contact the Firm Regarding Lead Plaintiff Deadlineglobenewswire.com
01:55PM
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCnewsfilecorp.com
10:01AM
WGS DEADLINE: The Gross Law Firm Reminds GeneDx Holdings Corp. Investors of Upcoming Securities Class Action Deadlineglobenewswire.com
06:55AM
MONDAY DEADLINE: GeneDx Holdings Corp. (WGS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announcesglobenewswire.com
04:08AM
GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGSprnewswire.com
03:14AM
GeneDx Holdings Corp. Investor Alert: Contact SBS by August 3, 2026 for Opportunity to Lead Securities Fraud Lawsuitprnewswire.com
Jul-30-26
Jul-30-2607:16PM
WGS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026newsfilecorp.com
Company

GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue443428305203235212179196
Cost of Goods Sold Incl. D&A140129111113261229175113
Gross Profit30329819490-27-17483
Selling, General and Administrative Excl. Other26223916819533831916469
Research and Development79724658861057335
Other Operating Expense-40418217699
Operating Income-34-12-23-181-668-446-242-30
Interest Expense43303321
Unusual Expense
————————
Non-Operating Income (Expense)-42-7-2647320431
Net Income Before Taxes-76-21-53-177-598-245-241-30
Income Taxes000-1-49000
Consolidated Net Income-78-21-52-176-549-245-241-30
Net Income From Continuing Operations-78-21-52-176-549-245-241-30
Net Income-78-21-52-176-549-245-241-30
EPS (Recurring)-2.66-0.73-1.94-7.23-53.63-74.93-33.16-4.26
EPS (Basic, Before Extraordinaries)-2.66-0.73-1.94-7.23-53.63-74.93-33.16-4.26
EPS (Diluted)-2.66-0.73-1.94-7.23-53.63-74.93-146.94-18.48
EBITDA-487-28-136-398-221-227-23
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio4.448.206.800.330.372.0812.21—
Gross Margin68.4069.6363.6144.33-11.49-8.022.2342.35
Operating Margin-7.67-2.80-7.54-89.16-284.26-210.38-135.20-15.31
Net Margin-17.61-4.91-17.05-86.70-233.62-115.57-134.64-15.31
Shares Outstanding2927272410366
Market Capitalization1,9683,5122,07566874422,186—
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$187.47$144.24$101.02$57.79$14.56● Close Price0.00M20.51M41.02M61.52M82.03MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ryan JasonDirectorJun 18 '26Option Exercise0.003,576015,480Jun 23
RUCH JOSHUADirectorJun 18 '26Option Exercise0.003,576033,299Jun 23
PFENNIGER RICHARD C JRDirectorJun 18 '26Option Exercise0.003,576045,082Jun 23
Meister Keith A.director, 10 percent owner:Jun 18 '26Option Exercise0.003,576023,705Jun 23
Leproust Emily M.DirectorJun 18 '26Option Exercise0.003,576024,852Jun 23
Casdin Elidirector, 10 percent owner:Jun 18 '26Option Exercise0.003,576024,093Jun 23
Feeley KevinCHIEF FINANCIAL OFFICERJun 16 '26Option Exercise0.007,197043,683Jun 18
Feeley KevinCHIEF FINANCIAL OFFICERJun 16 '26Sale60.773,729226,59739,954Jun 18
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 16 '26Option Exercise0.0018,7500114,873Jun 18
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 16 '26Sale60.7710,501638,104104,372Jun 18
Feeley KevinCHIEF FINANCIAL OFFICERJun 09 '26Option Exercise0.002,462037,752Jun 11
Feeley KevinCHIEF FINANCIAL OFFICERJun 09 '26Sale53.771,26668,07336,486Jun 11
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 09 '26Option Exercise0.006,546099,762Jun 11
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 09 '26Sale53.773,639195,66996,123Jun 11
Casdin Capital, LLCdirector, 10 percent owner:Jun 05 '26Buy52.8650,0002,642,8303,707,164Jun 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.